ABBOTT LABORATORIES
For the period ended Oct 16, 2024. Filed Oct 16, 2024.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 16, 2024 · Filed Oct 16, 2024
Contents
EX-99.1 · Diagnostics
Diagnostics
| Sales 3Q24 ($ in millions) | Total | Core Laboratory | Molecular | Point of Care | Rapid Diagnostics |
|---|---|---|---|---|---|
| U.S. | 1,032 | 332 | 37 | 103 | 560 |
| International | 1,380 | 982 | 91 | 43 | 264 |
| Total reported | 2,412 | 1,314 | 128 | 146 | 824 |
| U.S. | 1.8 | 4.5 | (2.8) | 6.0 | (0.2) |
|---|---|---|---|---|---|
| International | (3.8) | (1.5) | (3.9) | 0.7 | (12.2) |
| Total reported | (1.5) | — | (3.6) | 4.4 | (4.4) |
| Impact of foreign exchange | (2.9) | (4.3) | (1.5) | (0.2) | (1.4) |
| Organic | 1.4 | 4.3 | (2.1) | 4.6 | (3.0) |
| Impact of COVID-19 testing sales (3) | (1.9) | (0.2) | (3.9) | — | (3.4) |
| Organic (excluding COVID-19 tests) | 3.3 | 4.5 | 1.8 | 4.6 | 0.4 |
| U.S. | 2.4 | 4.8 | 4.5 | 6.0 | (1.0) |
| International | 3.8 | 4.4 | 0.8 | 1.3 | 2.8 |
As expected, Diagnostics sales growth in the third quarter was negatively impacted by year-over-year declines in COVID-19 testing-related sales 3. Worldwide COVID-19 testing sales were $265 million in the third quarter of 2024 compared to $305 million in the third quarter of the prior year.
Excluding COVID-19 testing-related sales, global Diagnostics sales increased 0.2 percent on a reported basis and increased 3.3 percent on an organic basis.
Excluding COVID-19 testing-related sales, global Core Laboratory Diagnostics sales grew 0.1 percent on a reported basis and increased 4.5 percent on an organic basis, led by continued adoption of Abbott's Alinity® family of diagnostics systems and testing portfolios.
| Sales 9M24 ($ in millions) | Total | Core Laboratory | Molecular | Point of Care | Rapid Diagnostics |
|---|---|---|---|---|---|
| U.S. | 2,775 | 969 | 112 | 308 | 1,386 |
| International | 4,046 | 2,879 | 272 | 133 | 762 |
| Total reported | 6,821 | 3,848 | 384 | 441 | 2,148 |
| U.S. | (16.2) | 5.6 | (12.3) | 6.6 | (29.8) |
|---|---|---|---|---|---|
| International | (2.4) | 0.3 | (7.2) | 4.8 | (10.6) |
| Total reported | (8.5) | 1.5 | (8.7) | 6.0 | (24.0) |
| Impact of foreign exchange | (2.9) | (4.8) | (0.8) | (0.1) | (1.1) |
| Organic | (5.6) | 6.3 | (7.9) | 6.1 | (22.9) |
| Impact of COVID-19 testing sales (3) | (10.4) | (0.2) | (6.3) | — | (25.0) |
| Organic (excluding COVID-19 tests) | 4.8 | 6.5 | (1.6) | 6.1 | 2.1 |
| U.S. | 3.0 | 5.9 | (3.3) | 6.6 | (0.1) |
| International | 5.9 | 6.7 | (0.9) | 5.1 | 5.7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.